BEIGENE, LTD.

(BGNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société BEIGENE, LTD.
01:01aBeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Swi..
BU
05/12BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hemato..
BU
05/09BEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/05BEIGENE, LTD. : Results of Operations and Financial Condition, Other Events, Financial Sta..
AQ
05/05BeiGene Reports First Quarter 2022 Financial Results
BU
05/04BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for P..
BU
04/29BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton Wes..
BU
04/28BEIGENE : Financial Information - Form 8-K
PU
04/28BEIGENE, LTD. : Results of Operations and Financial Condition, Other Events, Financial Sta..
AQ
04/28BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, ..
BU
04/27BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual..
BU
04/27Global Phase 3 Trial of BeiGene's PD-1 Inhibitor, Tislelizumab, in Combination with Che..
BU
04/26BeiGene Introduces Global Environmental, Social, and Governance Strategy
BU
04/25Biocytogen Signs RenMab™/RenLite™ Licensing Agreement with BeiGene
AQ
04/21BeiGene Provides Grant to Crossroads4Hope to Fund Psychosocial Support Programs for Can..
BU
04/20BEIGENE : China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamo..
PU
04/20BEIGENE, LTD. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ..
AQ
04/19BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tis..
BU
04/15China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell..
BU
04/12BEIGENE : Announces European Medicines Agency Acceptance of Marketing Authorization Applic..
PU
04/12BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
04/11IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Ver..
BU
04/08BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors ..
BU
04/06BeiGene Announces European Medicines Agency Acceptance of Marketing Authorization Appli..
BU
04/03SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beige..
PR
03/25SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beige..
PR
03/25BEIGENE : Current Report (Form 8-K)
PU
03/25BEIGENE, LTD. : Changes in Registrant's Certifying Accountant, Other Events, Financial Sta..
AQ
03/17BEIGENE : China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-Hi..
PU
03/17BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
03/16SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beige..
PR
03/15BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA..
BU
03/11China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or M..
BU
03/03BEIGENE, LTD. : Change in Directors or Principal Officers, Financial Statements and Exhibi..
AQ
03/03BeiGene Announces Health Canada Approval for BRUKINSA® (zanubrutinib) in Relapsed or Re..
BU
03/03BEIGENE : An announcement has just been published by the issuer in the Chinese section of ..
PU
03/01BeiGene to Present at the Cowen 42nd Annual Health Care Virtual Conference
BU
02/28BEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
02/25BEIGENE : Reports Fourth Quarter and Full Year 2021 Financial Results - Form 8-K
PU
02/25BEIGENE, LTD. : Results of Operations and Financial Condition, Other Events, Financial Sta..
AQ
02/25BeiGene Reports Fourth Quarter and Full Year 2021 Financial Results
BU
02/22BEIGENE : Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zan..
PU
02/22BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
02/22BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA..
BU
02/22BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (za..
BU
02/17BeiGene Announces Approval for BRUKINSA (zanubrutinib) by Swissmedic for Treatment of A..
BU
02/16BEIGENE, LTD. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
02/08BEIGENE : Initial Statement of Beneficial Ownership (Form 3)
PU
02/08BeiGene to Present at the Guggenheim Healthcare Talks - 2022 Oncology Conference
BU
02/02BEIGENE : Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors ..
PU
02/02BEIGENE, LTD. : Change in Directors or Principal Officers, Other Events, Financial Stateme..
AQ
02/01Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors
BU
01/31BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA..
AQ
01/28BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA..
BU
01/25BEIGENE : Announces Acceptance of a Supplemental New Drug Application in China for BRUKINS..
PU
01/25BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/24BeiGene Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combination w..
BU
01/21BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKIN..
AQ
01/20BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKIN..
BU
01/10BEIGENE : China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients..
PU
01/10BEIGENE, LTD. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ..
AQ
01/07BeiGene - China NMPA Approves Tislelizumab as Second or Third-Line Treatment for Patien..
AQ
01/06BeiGene to Present at the J.P. Morgan 40th Annual Healthcare Conference
BU
01/06China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients with L..
BU
2021BEIGENE : Expands Collaboration with Novartis to Develop and Commercialize BeiGene's TIGIT..
PU
2021BEIGENE, LTD. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Othe..
AQ
2021BeiGene Expands Collaboration with Novartis to Develop and Commercialize BeiGene's TIGI..
BU
2021BeiGene Announces Launch of Bioisland Innovation Center
BU
2021BEIGENE : Announces Closing of Its RMB22.2 Billion (US$3.5 Billion) Initial Public Offerin..
PU
2021BEIGENE, LTD. : Material Modification to Rights of Security Holders, Amendments to Article..
AQ
2021BeiGene Announces Authorisation of BRUKINSA (zanubrutinib) from the United Kingdom's MH..
AQ
2021BeiGene Announces Authorisation of BRUKINSA (zanubrutinib) from the United Kingdom's MH..
BU
2021BeiGene Announces Closing of Its RMB22.2 Billion (US$3.5 Billion) Initial Public Offeri..
BU
2021BEIGENE : Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ..
PU
2021BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
1  2  3  4  5  6  7  8Next